MARKET DYNAMICS

Amazon recently announced the launch of their online pharmacy, allowing customersto purchase generic medications, including insulin and inhalers, directly through its platform. Prime members without insurance can receive discounted medications, and all members will have their medications delivered directly to their doorstep without the need for an in-person pharmacy visit. Amazon first ventured into the sector with the $750 million PillPack acquisition in 2018, a startup focused on direct-to-consumerprescription drugs, which is likely to play a large role in this larger market play.

OPHTHALMOLOGY

Glenmark Pharmaceuticals has launched a generic version of Travoprost OphthalmicSolution USP, 0.004%, in the U.S., which isbioequivalent to the Sandoz brand TravatanZ. Glenmark's portfolio now includes 200products in the U.S. and 51 ANDAsubmissions awaiting FDA approval,highlighting their commitment to expanding their market presence and product offerings.

REGULATORY ACTION

Barriers to entry in the generics market are rising, driven by increased patent-related legal action as manufacturers defendexclusivity against competitors. Pfizer recently sued Sandoz,alleging its generic version of Inlyta, a kidney cancer treatment,infringes on a patent for crystalline forms of axitinib. Roche filed a similar lawsuit against Natco Pharma and ZydusLifesciences, challenging their FDA bids for generic versions of Evrysdi, the only noninvasive treatment for spinal muscularatrophy. Incyte also recently secured an injunction blocking SunPharma's generic JAK inhibitor Leqselvi, safeguarding Jakafi'smarket share until its patent expires in late 2026."

MARKET DYNAMICS

The European Commission has fined Teva, the world'slargest generic drugmaker, €462.6 million for abusingits dominant position by artificially extending the patent protection of its multiple sclerosis drug Copaxone andspreading misleading information about a competingproduct. Teva plans to appeal the decision, but the Commission asserts that enforcing competition laws in the pharmaceutical sector is essential for keeping drugs affordable, preserving treatment choices, and benefiting EU patients and national healthcare systems.

ANTIVIRALS

Gilead Sciences has reached royalty-free voluntarylicensing agreements with six generic manufacturers to produce and distribute generic versions of lenacapavir,an investigational HIV prevention drug, in 120 resource limited countries primarily across Africa and Asia. Theseagreements closely follow the release of results from the PURPOSE trials, which demonstrated the drug’ssuperiority over current standard PrEP medications.Regulatory filings are expected to begin by the end of2024, and Gilead plans to provide lenacapavir at noprofit until the generic manufacturers can fully meet market demand.

DIABETES & METABOLIC DISORDERS

As the demand for GLP-1 agonist treatments continues tosurge, several generic alternatives are nearing approval to enter markets across the globe. In the US, AmnealPharmaceuticals gained FDA approval for exenatide, one of the first generic GLP-1 injectables, while telehealthprovider Hims & Hers Health plans to offer a generic version of liraglutide (Victoza), expanding its existing GLP-1agonist offerings. In the UK, The British GenericManufacturers Association announced that at least four companies are poised to receive authorizations for generic weight loss drugs like liraglutide (formerly Saxenda and Victoza) to address UK supply shortages.